Background: Fibrates and niacin are at present the most effective therapies to increase plasma levels of high density lipoprotein-cholesterol (HDL-C); to date, limited data are available on their effects on HDL protective functions. Methods and results: Within a multicenter, randomized, open-label, cross-over study, 37 patients with metabolic syndrome received 6 weeks' treatment with fenofibrate or extended-release niacin (ER niacin), with a 4 weeks' wash-out period. HDL ability to preserve endothelial cell homeostasis was assessed by incubating cultured endothelial cells with HDL isolated from patients at baseline and after each treatment. HDL isolated from patients at baseline were as effective as control HDL in inhibiting vascular cell adhesion molecule-1 (VCAM-1) expression, but less efficient in promoting endothelial cell nitric oxide (NO) release. Both fenofibrate and ER niacin increased HDL ability to inhibit TNFα-induced VCAM-1 expression (+. 7% and +. 11%, respectively). Fenofibrate and ER niacin also improved the impaired HDL ability to induce the expression of endothelial nitric oxide synthase and NO production (+. 10% and +. 8%, respectively). Interestingly, HDL isolated after treatment showed an ability to promote endothelial NO release similar to HDL isolated from controls. No differences were observed between the two drugs. With both drugs, HDL function was improved irrespective of baseline HDL-C levels. Conclusion: Treatment with fenofibrate or ER niacin in patients with metabolic syndrome not only increased HDL-C levels but also improved the endothelial protective effects of HDL.

Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome / M. Gomaraschi, A. Ossoli, M.P. Adorni, E. Damonte, E. Niesor, F. Veglia, G. Franceschini, R. Benghozi, L. Calabresi. - In: VASCULAR PHARMACOLOGY. - ISSN 1537-1891. - 74(2015 Nov), pp. 80-86. [10.1016/j.vph.2015.06.014]

Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome

M. Gomaraschi
Primo
;
A. Ossoli
Secondo
;
G. Franceschini;L. Calabresi
2015-11

Abstract

Background: Fibrates and niacin are at present the most effective therapies to increase plasma levels of high density lipoprotein-cholesterol (HDL-C); to date, limited data are available on their effects on HDL protective functions. Methods and results: Within a multicenter, randomized, open-label, cross-over study, 37 patients with metabolic syndrome received 6 weeks' treatment with fenofibrate or extended-release niacin (ER niacin), with a 4 weeks' wash-out period. HDL ability to preserve endothelial cell homeostasis was assessed by incubating cultured endothelial cells with HDL isolated from patients at baseline and after each treatment. HDL isolated from patients at baseline were as effective as control HDL in inhibiting vascular cell adhesion molecule-1 (VCAM-1) expression, but less efficient in promoting endothelial cell nitric oxide (NO) release. Both fenofibrate and ER niacin increased HDL ability to inhibit TNFα-induced VCAM-1 expression (+. 7% and +. 11%, respectively). Fenofibrate and ER niacin also improved the impaired HDL ability to induce the expression of endothelial nitric oxide synthase and NO production (+. 10% and +. 8%, respectively). Interestingly, HDL isolated after treatment showed an ability to promote endothelial NO release similar to HDL isolated from controls. No differences were observed between the two drugs. With both drugs, HDL function was improved irrespective of baseline HDL-C levels. Conclusion: Treatment with fenofibrate or ER niacin in patients with metabolic syndrome not only increased HDL-C levels but also improved the endothelial protective effects of HDL.
Endothelial cells; Fenofibrate; High density lipoprotein; Niacin; Nitric oxide
Settore BIO/14 - Farmacologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1537189115001457-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 527.54 kB
Formato Adobe PDF
527.54 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/344475
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact